Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 120.3%.

  • BridgeBio Pharma's EBITDA Margin rose 68983700.0% to 120.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 172.39%, marking a year-over-year increase of 775900.0%. This contributed to the annual value of 267.22% for FY2024, which is 62615300.0% up from last year.
  • Per BridgeBio Pharma's latest filing, its EBITDA Margin stood at 120.3% for Q3 2025, which was up 68983700.0% from 121.45% recorded in Q2 2025.
  • BridgeBio Pharma's 5-year EBITDA Margin high stood at 19953.49% for Q4 2021, and its period low was 38200.0% during Q3 2022.
  • Over the past 5 years, BridgeBio Pharma's median EBITDA Margin value was 6377.94% (recorded in 2021), while the average stood at 6756.95%.
  • Within the past 5 years, the most significant YoY rise in BridgeBio Pharma's EBITDA Margin was 1244526700bps (2021), while the steepest drop was -388120600bps (2021).
  • Over the past 5 years, BridgeBio Pharma's EBITDA Margin (Quarter) stood at 19953.49% in 2021, then tumbled by -135bps to 6910.8% in 2022, then tumbled by -47bps to 10167.11% in 2023, then skyrocketed by 62bps to 3842.69% in 2024, then skyrocketed by 97bps to 120.3% in 2025.
  • Its EBITDA Margin stands at 120.3% for Q3 2025, versus 121.45% for Q2 2025 and 89.49% for Q1 2025.